RGNT Company Profile and Key Details

Regentis Biomaterials Ltd. (AMEX:RGNT) closed at $14.11 USD, gaining $12.61 (840.60%) from the previous close of $1.50. The stock is currently within 5% of its 52-week high $1.23 and $14.29. With a market capitalization of about $55.55 million, Regentis Biomaterials Ltd. is classified as a micro-cap and shows market-like volatility (beta ~0.92). Key stats such as the average daily volume over the past year has been around 2.02 million shares, trading with heavier-than-usual volume. Headquartered in Herzliya, None, Regentis Biomaterials Ltd. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Ehud Geller, the company employs approximately 10 people and listed since September 11, 2025. Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life.

Short-term trend indicators are bullishly aligned (SMA20 -15.58%, SMA50 -33.19%, SMA200 -34.87%). The stock’s 14-day RSI is 31.24 (weak momentum), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.63% below its high and over 6.89% above its low. Average 10-day trading volume of 19.14 million shares is significantly above the 3-month average of 1.99 million, indicating heightened recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Regentis Biomaterials Ltd. generated EPS of -$2.67 over the past year. Five-year average earnings growth is -71.58%.

Our AI price prediction model suggests that Regentis Biomaterials Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -18.67%, with price expected at $1.22 by June 26, 2026, within a range of $0.94 to $1.49 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by September 10, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -73.33%, with price at $0.40 by June 11, 2027, within a range of $0.20 to $0.46.

Regentis Biomaterials Ltd. (AMEX:RGNT) shares are flat 5.34% year-to-date currently trading near 52-week highs band. Our AI forecast model points to short-term weakness (-18.67% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-73.33% over one year), with expected trading ranges indicating moderate volatility.